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Summary The prognostic significance of c-erbB-2 oncoprotein overexpression detected in tumours by immunocytochemical assays (ICAs)
was investigated in 148 breast carcinomas. ICAs were performed under optimal technical conditions with frozen tissue sections and included
automated immunoperoxidase technique and computer-assisted analysis (densitometry) of digitized coloured microscopic images. Results of
quantitative ICAs (expressed in percentages of c-erbB-2-positive surfaces and mean optical densities) were correlated with the patients'
follow-up in axillary lymph node-positive (N+) and node-negative (N-) subgroups of patients. Patients' follow-up ranged from 9 months (forthe
first death) to 101 months (for the 121 alive patients) with a 62.5 months mean overall follow-up. It was shown that marked c-erbB-2
immunocytochemical expression in tumours (cut-off point 35%) significantly correlated with the patients' poor overall survival in N+ and in N
patients (Kaplan-Meier, log-rank test, P = 0.045 and P = 0.015). Also, marked c-erbB-2 immunohistochemical expression correlates with
short disease-free (P= 0.005), recurrence-free (P= 0.048) and metastasis-free survival (P= 0.05) (Kaplan-Meier, log-rank test) in N+, but not
in N- subgroups. It is concluded that in optimal conditions (automated and quantitative ICAs on frozen sections) c-erbB immunohistochemical
expression is a significant prognostic indicator in terms of overall and disease-free survival. The c-erbB-2 protein prognostic significance is
independent of node status in terms of overall survival, but not of disease-free survival.
Keywords: automated immunoperoxidase; image analysis; quantitative immunocytochemical assay; c-erbB-2; breast carcinomas;
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The prognosis of patients with operable breast cancers is
extremely variable. Among the prognostic indices recognized as
independent prognostic indicators, axillary nodal status is gener-
ally accepted tobe the mostimportantprognostic factorin patients
with operable cancers. However, axillary lymph node invasion
considered as a prognostic factor lacks sensitivity, since 30%
of patients with pathologically negative nodes relapse and die
within 10 years (McGuire et al, 1992). This observation has led
to a search for new accurate prognostic indicators in breast
carcinomas.
Molecular biology studies have demonstrated the amplification
and overexpression of some oncogenes in breast cancers. Slamon
et al (1987, 1989) showed that the c-erbB-2 gene was amplified
in 27% of breast carcinomas. Further studies confirmed these
findings, showing that c-erbB-2 amplification could be found in
10-40% of breast cancers (see review in Charpin et al, 1993;
Ravdin et al, 1995). Most of these studies revealed that c-erbB-2
amplification was correlated with an overexpression (mRNA) and
with an increase of the synthesis of p185 kDa-encoded protein.
Amplification and overexpression of the c-erbB-2 oncogene
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detected by Southern and Northern blotting have been shown to
correlate with the c-erbB-2 oncoprotein expression evaluated by
Western blotting and immunocytochemistry (Slamon et al, 1987,
1989), suggesting that immunohistochemistry is suitable for
evaluating the c-erbB-2 gene dysregulation in breast cancers.
The major practical relevance of c-erbB-2 amplification and
overexpression with increased production of c-erbB-2 was first
noted by Slamon et al (1987). This report and the following one
(Slamon et al, 1989) demonstrated that c-erbB-2 was significantly
correlated with the clinical outcome of patients with metastatic
axillary lymphnodes. Some furtherpublications demonstrated that
c-erbB-2 amplification and overexpression were significant prog-
nostic indicators, independent of other current prognostic factors
(Van de Vijver et al, 1988; Walker et al, 1989; Tandon et al, 1989;
Wright et al, 1989; McCann et al, 1991; Paterson et al, 1991;
Winstanley et al, 1991). Other studies, however, could not demon-
strate that c-erbB-2 amplification or overexpression did have
prognostic significance (Shou et al, 1989; Heintz et al, 1990; Kury
et al, 1990; Clark et al, 1991; McCann et al, 1991; Ravdin et al,
1995). This controversy may arise from variations in the series
size, technical procedures and/or statistical methods of analysis
(Ravdin et al, 1995; Pauletti et al, 1996). In particular, discrepan-
cies in immunocytochemical studies may result from tissue fixa-
tion (Slamon et al, 1987, 1989; Tandon et al, 1989; Clark et al,
1991; Paterson et al, 1991; Winstanley et al, 1991; Piffanelli et al,
1996) and from the lack of standardized means of evaluating
immunostaining (Tandon et al, 1989; Charpin et al, 1993).
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In the present study, our goal was to investigate the prognostic
significance in terms of overall and disease-free follow-up
(8.4 years) of c-erbB-2 immunolabelling of 148 breast carci-
nomas, investigated by immunohistochemistry performed in
optimal technical conditions including (1) frozen sections; (2)
automated immunohistochemical procedure (Ventana device);
A
C
Figure 1 Immunoperoxidase, frozen sections, MAb anti-c-erbB-2
protein/CB1 1 in breast carcinomas. (A) Strong positive immunoreaction
within cell cytoplasm and cell membrane in ductal invasive carcinoma grade
2. (B) Intermediate pattern of staining with heterogeneous distribution of
positive reaction in intraductal component of invasive ductal carcinoma.
(C) Very weak staining in invasive ductal carcinoma grade 2
and (3) quantification of immunostaining by computer-assisted
analysis ofdigitized microscopic images (SAMBAdevice).
MATERIALS AND METHODS
Materials
Patients (n = 148) presenting with palpable or impalpable breast
carcinomas and who had not received any kind of adjuvant
chemotherapy or endocrine therapy were operated on from
January 1986 to May 1987. Patients' follow-up ranged from 9
months to 101 months (mean = 62.5 months, s.d. = 25 months;
median = 64.9 months). At 101 months (8.4 years), the records
showed that 121 out of 148 patients were alive (82%), 27 out of
148 patients (18.2%) were deceased and 20 out of 148 (13.5%)
had developed distant metastases, whereas 16 out of 148 (10.6%)
had a local relapse. Patients' ages ranged from 34 to 79 years
(mean = 53.2 years, s.d. = 12.3 years). The tumours' sizes ranged
from 4 mm to 51 mm (mean = 22.5 mm, s.d. = 18.5 mm).
The histological examination of the surgical specimens was
performed on paraffin sections stainedby haematoxylin, eosin and
saffronin. All the tumours were invasive carcinomas. Most (65%)
were of ductal type (n = 96/148), whereas the remainder were of
lobular type (n = 37/148, 25%) or of various histological types
(n = 15/148, 10%), including mucinous (n = 3), tubular (n = 4),
medullary (n = 5), papillary (n = 1), apocrine (n = 1) and cribri-
form mixed (n = 1). Ductal invasive carcinomas (Bloom et al)
grade 1 accounted for 16% of the tumours, grade 2 for 59% and
grade 3 for 25%. Axillary lymph node dissection was performed in
140 out of 148 patients. The mean number ofnodes found in axil-
lary resection was 14.2 (s.d. = 5). The histological examination
showed that 66 out of 140 (47%) patients were node positive and
74 out of 140 (53%) node negative. Node-positive patients had
more than three metastatic lymph nodes in 21 out of66 cases.
Immunostaining and image analysis
Tissue
Tissue fragments were sampled for immunostaining by a patholo-
gist immediately after the intraoperative diagnosis performed on
frozen sections. The size ofthe fragments frozen varied according
to the tumour size (an average of 5 x 4 x 2 mm). The fragments
were sampled in dense tumour areas, lacking grossly visible
adipose tissue, promptly dipped in liquid nitrogen and stored at
- 80°C in the laboratory tumour library (tumours collected for
prospective study since 1986). Immunodetections were perforrned
on 5-,um-thick sections (cryostat Leica 3000, Rueil Malmaison,
France).
Immunoperoxidase
Monoclonal (MAb) mouse anti-human c-erbB-2 oncoprotein
(CB11) was purchased from Biogenex (Menarini, Chevilly Larue,
France). Immunoperoxidase technique was performed using an
automatic immunostaining device (Ventana, Medical System,
Tucson, AR, USA) and Ventana kits (Strasbourg, France) (Grogan
et al, 1993, 1995).
Image analysis
Immunostaining was analysed using an Axiophot microscope
(Zeiss) and a 3 CCD Sony camera and then processed in an image
analysis device (SAMBA 2005, Alcatel TITN, Grenoble, France)
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Table 1 Overall survival of patients (8.4-year follow-up) correlated with the
c-erbB-2 protein immunostained (automated immunocytochemical on frozen
sections) surfaces (mean surfaces evaluated by computer-assisted analysis
of digitized microscopic images, cut-off point 35%) in 148 invasive breast
carcinomas
c-erbB-2 immunostained surface (%)
Overall survival < 35% > 35%
All patients
Alive 71/121 50/121
Deceased 13/27 14/21
Node-negative patients
Alive 34/66 32/66
Deceased 7/8 1/8
Node-positive patients
Alive 34/49 15/49
Deceased 6/17 11/17
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Figure 2 Distribution of c-erbB2 (Her-2 neu) immunostained surface in 148
breast carcinomas, evaluated by automated (Ventana) immunoperoxidase on
frozen sections: quantitation by computer-assisted analysis (SAMBA) of
digitized coloured microscopic images (ordinate, % of patients; abscissa, %
of immunostained surface vs counterstained surfaces)
(Brugal et al, 1979). The two parameters of the densitometric
analysis, the percentages of positive immunostained surfaces
(membrane and cytoplasm) vs counterstained surface and mean
optical density (MOD), which depends upon the staining intensity
(SAMBA arbitrary units scale: 0-255), were obtained as reported
previously (Charpin et al, 1988, 1992, 1993, 1994, 1995a, b).
Statistical analysis
Analysis ofdisease-free and overall survival was performed using
the Kaplan-Meier method. The difference between curves was
evaluated with the Mantel-Cox test (or log-rank test) for censored
survival or events observation. All computations were done with
BMDP statistical software (University of California, Berkeley,
CA, USA). The percentages ofc-erbB-2 stained surface evaluated
by image processing device were stratified and correlated with
majorevents during the course ofthe disease (distantmetastases or
local recurrences) and with overall survival in order to define
immunohistochemical thresholds of prognostic significance. The
optimal c-erbB-2 protein cut-offpoint ofpositive surface endowed
D0
Node-positive patients
(overall survival)
Her> 35%
P= 0.015
0 20. 40 60
Time (months)
Figure 3 Overall survival (8.4-year follow-up) of patients (n = 148) correlated
to c-erbB2 (Her-2/neu) protein immunostained surface (mean surface per
tumour evaluated by computer-assisted image analysis of digitized
microscopic images, cut-off point 35%). (A) In node-negative patients and in
(B) in node-positive patients (Kaplan-Meier, log-rank test, BMDP)
with prognostic significance was determined after statistical vali-
dation (Altman et al, 1994).
RESULTS
c-erbB-2 distribution in tissue sections
c-erbB-2 immunohistochemical expression was similar to that
already observed in tumour cells (Charpin et al, 1992, 1993). All
the invasive tumours were c-erbB-2 positive, but the immuno-
staining distribution was heterogeneous. Some tumours were
markedly positive and others faintly positive (Figure 1). However,
theheterogeneity ofc-erbB-2 expression essentially concerned the
surfaces ofimmunostaining, whereas the intensity ofstaining was
most often homogeneous and strong.
The variation inthec-erbB-2-positive surfaces ontissue sections
is shown in the histogram in Figure 2. C-erbB-2-positive surfaces
evaluated by computer-assisted image analysis varied from 0.1%
to 98% (mean = 34%, s.d. = 25%). The mean optical densities
reflecting the intensity of staining varied from 65 to 91 arbitrary
units (mean = 77, s.d. = 13). Since the staining intensity was not
significantly variable in the series investigated, this parameter was
notusedforthecorrelative studies with thepatients' follow-up. For
the same reasons, the quantitative immunocytochemical (QIC)
index was useless and not worthy ofstatistical analysis.
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Table 2 Disease-free survival of patients (8.4-year follow-up) correlated with
c-erbB-2 protein immunostained (automated immunocytochemical assays on
frozen sections) surface (mean surfaces evaluated by computer-assisted
analysis of digitized microscopic images, cut-off 35%) in 148 invasive breast
carcinomas
c-erbB-2 protein immunostained surface (%)
Disease-free survival < 35% > 35%
All patients
No disease 65/108 43/108
Disease 19/40 21/40
Node-negative patients
No disease 30/58 28/58
Disease 11/16 5/16
Node-positive patients
No disease 33/46 13/46
Disease 7/20 13/20
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Table 3 Recurrence-free survival of patients (8.4-year follow-up) correlated
with c-erbB-2 protein immunostained (automated immunocytochemical
assays in frozen sections) surface (mean surfaces evaluated by computer-
assisted analysis of digitized microscopic images, cut-off 35%) in 148 breast
carcinomas
c-erbB-2 product immunostained surface (%)
Recurrence-free survival < 35% > 35%
All patients
No recurrence 78/132 54/135
Recurrence 5/16 10/16
Node-negative patients
No recurrence 37/65 28/65
Recurrence 4/9 5/9
Node-positive patients
No recurrence 39/61 22/61
Recurrence 1/5 4/5
Table 4 Metastasis-free survival of patients (8.4-year follow-up) correlated
with c-erbB-2 immunostained (automated immunocytochemical assays in
frozen sections) surface (mean surfaces evaluated by computer-assisted
analysis of digitized microscopic images, cut-off 35%) in 148 breast
carcinomas
c-erbB2 protein immunostained surface (%)
Metastasis-free survival < 35% > 35%
All patients
No metastases 75/128 53/128
Metastases 9/20 11/20
Node-negative patients
No metastases 37/68 31/68
Metastases 4/6 2/6
Node-positive patients
No metastases 35/53 18/53
Metastases 5/13 8/13
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Figure 4 (A) Disease-free survival, (B) recurrence-free survival and
metastasis-free survival (8.4 year follow-up) of patients (n = 148) correlated
to c-erbB2 (Her-2/neu) protein immunostained surface (mean surface per
tumour) evaluated by computer-assisted analysis (SAMBA) of digitized
coloured microscopic images, cut-off point 35% in N+ patients (ordinate, per
cent of patients; abscissa, per cent of immunostained surface vs
counterstained surface)
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c-erbB-2 immunohistochemical expression and
patients' survival
c-erbB-2 and overall survival (Table 1)
c-erbB-2-Immunostained Surfaces (cut-off point 35%) signifi-
cantly correlated with the patients' overall survival. Tumours with
a large c-erbB-2-positive surface have a poorer survival than those
with a small c-erbB-2-positive surface (Table 1). When the entire
patient series was stratified into node-positive (N+ = 66) and node-
negative (N- = 74) tumours, a significant c-erbB-2 (>35%) correla-
tion with poor survival was observed in N- (P = 0.045) patients
(Figure 3A) and in N+ (P = 0.015) patients (Figure 3B).
c-erbB-2 and disease-free survival (Table 2)
Marked c-erbB-2 protein expression in tissue correlated (P=
0.015) with low disease-free survival, but only in N+ (P = 0.005)
patients (Figure 4A) not in N- (P = 0.17) patients.
c-erbB-2protein and recurrence-free survival (Table 3)
Large c-erbB-2-positive surfaces also correlated (P = 0.048) with
low recurrence-free survival in N+ patients (Figure 4B) but not in
the N- subgroup (P = 0.23) ofpatients.
c-erbB-2 and metastasis-free survival (Table 4)
Marked c-erbB-2 protein immunohistochemical expression corre-
lated with metastasis-free survival in N+ patients (P = 0.05)
(Figure 4C) but not in N- patients (P = 0.1).
DISCUSSION
The practical clinical relevance of c-erbB-2 overexpression is
related to its prognostic significance in breast carcinomas (Slamon
et al, 1987, 1989) and to its value, recently reported, in predicting
response to certain adjuvant therapies (Stal et al, 1995).
The prognostic value of the c-erbB-2 oncogene in breast
carcinomas has been controversial, although now there is some
evidence from the recent literature of its prognostic significance
(Borg et al, 1990). Amplification ofc-erbB-2 has been reported as
a significant predictor of both overall survival and relapse time in
patients with breast cancers (Slamon et al, 1989; Tandon et al,
1989; Wright et al, 1989) or simply as a predictor ofrelapse (Van
de Vijver et al, 1988; Press et al, 1993).
Furthermore, c-erbB-2 amplification has been given a greater
prognostic value than most currently used prognostic factors,
including hormonal receptors in positive lymph node patients
(Slamon et al, 1989) and some ofthe immunocytochemical studies
showed similar results (Gusterson et al, 1988; McCann et al,
1991). Some studies showed that c-erbB-2 overexpression was a
marker of poor prognosis in N+ patients (Slamon et al, 1989;
Tandon et al, 1989; Borg et al, 1990; Lipponen et al, 1993; Quenel
et al, 1995), while others identified c-erbB-2 as a marker of poor
prognosis in the N- subgroup of patients (Paterson et al, 1991;
Press et al, 1993). In our study, c-erbB-2 immunodetectable over-
expression correlated with poor overall survival in the N+ and N-
subgroups of patients, and with shorter disease-free survival only
in N+ patients. However, the lack of statistical prognostic signifi-
cance in terms of recurrence and metastasis-free survival in N-
patients may result from fewer deaths in the N- subset compared
with the N+ subset ofpatients.
Most of the discrepancies in the reports probably result at least
partly from the lack of standardized methodologies, particularly
for immunohistochemistry.
The amplification and overexpression are correlated with an
increase in the encoded protein production detected by Western
blots or immunoenzyme assays (Slamon et al, 1989; Quenel et al,
1995; Piffanelli et al, 1996). Clark et al (1991) established that
only the expression of five copy amplification could be detected
on paraffin sections. The c-erbB-2 protein antigenic properties are
stable and preserved even after formalin fixation and paraffin
embedding. Southern, Northern and Western blots, as well as
immunochemistry and fluorescence in situ hybridization (FISH),
can be assessed in archival breast cancer specimens to detect
c-erbB-2 amplification or overexpression, although FISH was
recently found to be superior to all methodologies in fixedparaffin-
embedded tissue (Pauletti et al, 1996). However, whatever the
method used, fixation and paraffin embedding are responsible for a
certain loss ofantigenicity, as shown by the comparison ofimmun-
odetections performed on paraffin sections and on frozen sections
(Tandon et al, 1989; Winstanley et al, 1991; Heatley et al, 1993).
Therefore, although paraffin sections are suitable for c-erbB-2
immunocytochemical assays (ICAs) c-erbB-2 oncoprotein ICAs
on frozen sections enable elimination of technical bias as a result
oftissue fixation and paraffin embedding. In our view, in order to
standardize methodologies, ICAs should be performed on frozen
tissue samples, although freezing tissue and storing samples at
-80°C is not always easy to achieve.
Similarly, the reproducibility of immunocytochemical tests is
better assessed by automated devices, as in our study, than by
manual techniques. With the automated devices, many sections
can be run at the same time in exactly the same conditions. Tests
can be more rapidly assessed and the results provided are more
appropriate correlative studies.
Finally, the evaluation of results of the oncoprotein immuno-
detections by computer-assisted analysis of digitized microscopic
images provides for more accurate data than semi-quantitative
analysis, which depends on observer experience and subjectivity.
Moreover, results of densitometry by image analysis of tissue
sections consist in quantitative data also more appropriate for
statistical analysis, in particular for determining the cut-off point
ofprognostic significance.
Quantitative immunocytochemistry has already been developed
on a different system for c-erbB-2 ICAs (Baak et al, 1991; Bacus
et al, 1990a, b; Charpin et al, 1992, 1993; Press et al, 1993). In one
study (Press et al, 1993), the quantitative c-erbB-2 ICAs were
related to the patients' follow-up. In this study, detection was
performed on paraffin sections using a polyclonal antibody. It was
shown that breastcarcinomas with high overexpression ofc-erbB-
2 oncoprotein were associated in node-negative patients with a
risk of recurrence 9.5 times greater than those with low c-erbB-2
expression (Press et al, 1993). In our study, we obtained different
results, although we also used computerized image analysis,
probably because we used different antibodies and frozen-tissue
samples. Quantitative immunochemistry, as assessed in our study,
was developed to standardize immunohistochemical assays.
The term, quantitative assay, only refers to quantitation of the
immunostaining and cannot, therefore, pretend to quantify the
antigens themselves, since immunohistochemical signals are
the results of a series of amplification reactions that may not
reflect the true receptor level within the samples.
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In conclusion, using automated (Ventana device) and quantita-
tive (SAMBA system) immunohistochemical assays on frozen-
tissue samples of breast carcinomas, we showed that strong
c-erbB-2 expression (cut-offpoint 35%) correlated with poorer 8-
year overall survival in N+ and N-patients and shorter disease-free
survival in N+ patients compared with weak c-erbB-2 immuno-
expression.
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